Clinical Trial Update: A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures [Phase 3]

View source ↗

Summary

Phase 3 study of perampanel (E2007) as adjunctive therapy in refractory partial-onset seizures completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial-onset Seizures

Drugs mentioned

• Perampanel (perampanel)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Partial-onset Seizures | Phase 3 | Status: COMPLETED | Results posted: 2020-06-05